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Abstract
Several lines of evidence support the hypothesis that hematopoietic stem cells (HSCs) directly interact with the
immune system and have potential for immune privilege. Although the microenvironment or niche provides
protection for HSCs from immune attack, HSCs are also capable of interacting with the immune system as signal
“providers” and signal “receivers”. On the one hand, HSCs display surface immune inhibitory molecules to evade
the attack from the innate and adaptive immune systems; on the other hand, HSCs are capable of directly sensing
the signals from the immune system through their surface receptors. Thus, HSCs are important direct players in the
immune system.
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Introduction
The immune properties of pluripotent stem cells and tis-
sue-specific stem cells have been attracting research inter-
est. Based on the observation that embryonic stem (ES)
cells express low levels of HLA class I and hardly any
HLA class II proteins, it was initially suggested that ES
cells are not recognized by the host immune system. How-
ever, well-designed experiments by Swijnenburg et al.
clearly demonstrated that human ES cells were rejected
upon transplantation into immune-competent recipient
mice [1]. A novel study by Zhao et al. also showed that
induced pluripotent stem (iPS) cells could trigger an
immune response even in syngeneic recipients [2]. There-
fore, it appears that pluripotent ES cells and iPS cells are
not immune privileged. By contrast, some adult stem cells,
such as mesenchymal and amnion stem cells are immune
privileged to a certain extent. These cells are capable of
avoiding rejection in intra- and even inter-species trans-
plantation through the production of immunosuppressive
molecules [1,3].
Hematopoietic stem cells (HSCs) are responsible for
the daily production of all blood and immune cells in the
body and have been widely used in transplantation to
treat patients with leukemia, lymphoma, some solid
cancers, and autoimmune diseases [4]. Although freshly
isolated HSCs are known to have a very slim possibility
of escape from immune rejection upon allogeneic trans-
plantation, current evidence suggests that in vivo the
HSC niche provides an immune-privileged site for HSCs.
Moreover, HSCs per se also possess certain potential for
immune privilege through the regulation of the expres-
sion of surface immune molecules. This short review,
does not intend to cover the entire topic of the roles of
HSCs in immunity; rather it seeks to provide an update
of the recent progress toward the understanding of how
HSCs survive immune-mediated elimination and how
they contribute to immunity.
HSCs in niches: immune privilege offered by regulatory
T cells
In vivo, stromal cells and other cells form a complex
microenvironment for HSCs that controls their multiple
fates, including quiescence, apoptosis, and migration as
well as the cell divisions that lead to formation either of
daughter HSCs or of lineage-committed progenitors that
are capable of limited proliferation. Currently, we know
of the existence of several types of cells that form bone
marrow HSC niches [5]. The endosteal HSC niche con-
tains osteoblasts as the main supportive cell type for
maintenance of hematopoiesis [6,7]. The vascular HSC
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any medium, provided the original work is properly cited.niche is mainly composed of sinusoidal endothelial cells
[8]. More recently, it was suggested that these two types
of cells may establish a compound niche [9,10]. In addi-
tion, SDF-1 abundant reticular (CAR) cells [11], CD146-
expressing subendothelial stromal [12], Nestin
+ mesench-
ymal stem cells [13], macrophages [14,15], and the
sympathetic nervous system [16] have also been demon-
strated to represent components of HSC niches [5].
A recent elegant study by Fujisaki et al. using high-
resolution in vivo imaging demonstrated that regulatory
T cells (Treg) colocalize with HSCs in the endosteal
area in the bone marrow to protect HSCs from immune
attack [17]. IL-10 produced by these Treg cells plays an
essential role in this immune protection. This novel
finding suggests that the HSC niche not only specifies
an environment to control the cell fates of HSCs, but it
may also provide an immune-privileged site for HSCs
[17].
CD47: innate immunity of HSCs
Whereas the niche offers protection for HSCs from
immune attack, HSCs are capable of migrating in and
out of the niche [18], which drastically increases the
possibility that they will interact with the immune sys-
tem. It is evident that HSCs outside of the niche appar-
ently are capable of protecting themselves from innate
macrophage phagocytosis.
CD47, also known as integrin-associated protein, binds
to the signal regulatory protein alpha on macrophages
and inhibits phagocytosis. Weissman’s group showed that
it is expressed on freshly isolated bone marrow HSCs at a
relatively low level, suggesting that the possibility of the
potential interaction between HSCs and the innate
immune system within the stem cell niche is small.
When HSCs are activated by potent inflammatory signals
and mobilize into circulation, the CD47 level is dramati-
cally upregulated on the surface of HSCs [19]. Similarly,
CD47 is also upregulated on a variety types of blood can-
cer and solid cancer cells [20]. It was suggested that the
increased expression of CD47 on the surface of mobilized
HSCs and cancer cells protects these cells from phagocy-
tosis [20].
CD274: adaptive immunity of HSCs
In addition to evading the potential attack from the
innate immune system, HSCs also have tricks that pro-
tect them against the adaptive immune system. CD274
(B7-H1 or PD-L1) is a member of the B7 family that is
expressed on dendritic cells, activated immune cells, and
parenchymal cells under certain condition and on cells in
immune-privileged sites such as eyes and placenta where
it inhibits T cell or innate activation [21,22]. CD274 is
also selectively expressed by various cellular components
in the tumor microenvironment, where it inhibits tumor-
specific T-cell immunity by inducing T cell apoptosis and
delaying rejection [21].
We recently provided evidence demonstrating that
HSCs possess the ability to regulate their surface expres-
sion of CD274 in order to evade the rejection by the
acquired immune system [23]. We showed that CD274
is expressed on freshly isolated bone marrow HSCs at a
low level in vivo [23]. These are similar to the scenario
of CD47. Surprisingly, after in vitro culture, HSCs upre-
gulate the surface expression of CD274 10-fold, which
efficiently inhibits host T cell proliferation upon allo-
graft transplantation [23]. These observations clearly
indicate that ex vivo culture significantly modulates the
immunogenicity of stem cells. Therefore, in striking
contrast to pluripotent stem cells, HSCs have modulata-
ble immune privilege that can overcome allogeneic
immune barrier, and HSCs can directly participate in
adaptive immunity.
Fiorina et al. demonstrated that CD274 is upregulated
on mouse splenic Lin
-Kit
+ hematopoietic cells after the
treatment of an antagonist of chemokine CXCR4 [24],
suggesting that the CD274 level on phenotypic hemato-
poietic progenitors can be increased upon mobilization.
Whether the expression of CD274 on primitive and func-
tional HSCs or blood cancer cells can be physiologically
regulated in vivo and its biological significance warrants
further investigation. Moreover, the future identification
of additional immune molecules whose alterations (either
up or down) can regulate allograft acceptance will enable
the complete resolution of the issue of immune rejection
in allogeneic transplantation.
HSC activation by infection
While the existence of niche and the expression of
immune inhibitors on HSCs enable HSCs to evade
immune attack, it is also clear that HSCs can directly
respond to pathogen-specific infection through sys-
tematic cytokine stimulation from both innate and
adaptive immune signals. Several classes of signaling
receptors expressed on HSCs that bind to cytokines or
infectious ligands directly participate in the infection
response: IFN receptors [25-27], TNF receptor [28-30],
and Toll-like receptors (TLR) [31-33] (see review by
Goodell’s group [34]). In general, the infection or
inflammatory signals activate HSCs and chronically
lead to accelerated differentiation at the expense of
loss of HSC potency [27]. The differentiation produces
immune effector cells that counteract the initial infec-
tion. By contrast, the aberrant IFN and TNF signaling
are associated with myelodysplastic syndrome and
bone marrow failure [34]. We predict that additional
immune-related surface signaling receptors also regu-
late the cell fates of HSCs. For example, the identifica-
tion of the receptors for Angiopoietin-like proteins
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of inflammatory Angptls on HSCs (unpublished data).
Model of the interplay between HSCs and the immune
system
Based on these recent progress, we propose a model for
the interaction between HSCs and the immune system.
Within the niche, HSCs are protected by Treg cells from
potential immune attack. Outside the niche, HSCs are
capable of directly interacting with the immune system
through surface immune molecules for “out” signaling
and “in” signaling (Figure 1).
The “out” signaling is mediated by factors such as CD47
and CD274 that inhibit attack from the innate immunity
and adaptive immunity responses, respectively. Based on
the results discussed here, we hypothesize that homeo-
static HSCs express low levels of surface immune suppres-
sors, and the levels of these suppressors can be induced by
stress or immune signals. These immune suppressors may
thus modulate HSC immunogenicity and, therefore, con-
tribute to the “immune privilege” of HSCs. This regulata-
ble “immune privilege” should be advantageous to HSCs
as it should allow these important stem cells to rapidly
adjust to altered environmental conditions or protect
them from excessive immune activation/inflammation or
potential autoimmune disorders.
The stimulatory “in” signaling from inflammation acti-
vates HSCs and induces differentiation through surface
receptors including TLR, TNFR, IFNR, and others. This
activating “in” signaling should be counter-balanced by
the environmental cues within the stem cell niche,
which maintain the quiescence and stemness of HSCs.
The continuing investigation of this area may open up a
new scientific field - the immunology of stem cells. We
speculate that a common mechanism exists for regula-
tion of immune signals in some other types of stem
cells. It will be interesting to study the immunology of
stem cells by investigating the roles of surface immune
molecules and receptors on ES cells, iPS cells, other
adult stem cells, and cancer stem cells.
Open questions
The following questions must be addressed to pro-
vide new insights into the understanding of immu-
nology of stem cells:
Figure 1 A model of the interplay between HSCs and the immune system. HSCs express surface immune molecules for “in” signaling and
“out” signaling that directly dialog with the immune system. Whereas the “out” signaling, mediated by surface molecules such as CD47 and
CD274, inhibits attack from the innate immunity and adaptive immunity responses, respectively, the stimulatory “in” signaling from inflammation
activates HSCs and induces differentiation through surface receptors including TLR, TNFR, IFNR, and others.
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CD47 and CD274 are expressed on HSCs and other
stem cells that modulate the immunogenicity of
stem cells?
2) Do HSCs express immune stimulatory molecules?
Probably yes. If so, what are their functions in mod-
ulating other immune cells?
3) How is the expression of immune surface mole-
cules regulated in vivo? What is the mechanism for
the potential upregulation of immune suppressors
and downregulation of immune stimulators? Do sur-
face immune molecules change their expression on
HSCs upon mobilization, infection, and in extrame-
dullary organs?
4) HSCs can interact with immune system as signal
providers (“out” signaling) and as signal receivers
(“in” signaling). What is the connection between the
“in” signaling and “out” signaling? Can “in” signaling
modulate the type and magnitude of “out” signaling
and vice versa? The study of CD274 may provide
more insight into this question. For example, CD274
is not only a ligand for PD-1 and CD80 (thus provid-
ing “out” signaling) but is also a counter-receptor of
PD-1 that may deliver the reverse “in” signaling.
5) Can HSCs sense signals from the immune system
to attenuate their activation? Does this help maintain
their stemness?
6) Do human and mouse stem cells have similar
immunology? For example, do CD274 and other sur-
face immune molecules play similar roles in both
species?
7) Does the aberrant immune property of stem cells
cause diseases?
8) What are the expression and functions of surface
immune molecules and receptors on other stem cells
including ES cells, iPS cells, other tissue specific
stem cells, and cancer stem cells?
Conclusion
Recent evidence suggests that HSCs are immune privi-
leged within the in vivo bone marrow niche. Neverthe-
less, HSCs are also capable of interacting with the
immune system as signal “providers” and signal “recei-
vers”. As signal providers, HSCs display surface immune
inhibitory molecules to suppress the innate and adaptive
immune systems. As signal receivers, HSCs directly sense
systematic immune signals through their surface recep-
tors and change their cell fates in response to the altered
immune environment. HSCs thus directly interact with
the immune system. The data discussed here mark the
start of a series of investigations that may open up a new
field - the immunology of stem cells.
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